IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Lonza and Human Genome Sciences Sign Manufacturing Agreement

11:55 PM MDT | July 12, 2010 | Deepti Ramesh

Lonza says it has entered into an agreement with Human Genome Sciences (HGS; Rockville, MD) for the future commercial supply of Benlysta (belimumab), which is currently under regulatory review in the U.S. and Europe as a potential new treatment for systemic lupus erythematosus (SLE). Benlysta is being developed by HGS and GlaxoSmithKline (GSK; London) under a co-development and commercialization agreement entered into in 2006. GSK submitted a marketing authorization application last month to the European Medicines Agency, seeking approval to market belimumab in...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa